FGFR2 and neoplasm: Treatment with PD173074 selectively and potently inhibited growth of FGFR2-amplified GC cell lines (KATOIII, SNU-16, and OCUM-2M), leading to a strong decrease in tumor cells in S phase accompanied by an increase in tumor cells in the sub-G1 population [38].